73628 Federal Register / Vol. 79, No. 238 / Thursday, December 11, 2014 / Notices 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

— Evaluate whether and if so how the 

quality, utility, and clarity of the 

information to be collected can be 

enhanced; and 

— Minimize the burden of the 

collection of information on those 

who are to respond, including 

through the use of appropriate 

automated, electronic, mechanical, or 

other technological collection 

techniques or other forms of 

information technology, e.g., 

permitting electronic submission of 

responses. 

Overview of this information 

collection: 

(1) Type of Information Collection: 

New collection under activities related 

to the National Crime Victimization 

Survey Redesign Research (NCVS–RR) 

program: NCVS Subnational Companion 

Study—American Crime Survey Field 

Test. 

(2) The Title of the Form/Collection: 

American Crime Survey (ACS). 

(3) The agency form number, if any, 

and the applicable component of the 

Department sponsoring the collection: 

The form number for the questionnaire 

is ASC1 and ASC2. The applicable 

component within the Department of 

Justice is the Bureau of Justice Statistics, 

in the Office of Justice Programs. 

(4) Affected public who will be asked 

or required to respond, as well as a brief 

abstract: Adults ages 18 or older in 40 

largest Core Based Statistical Areas 

(CBSAs) in the United States, as 

measured by the number of households. 

Since 2008, BJS has initiated numerous 

research projects to assess and improve 

upon the core NCVS methodology. The 

purpose the Companion Survey Field 

Test will be to test a low-cost alternative 

self-administered survey for collecting 

information about violence and property 

crime to generate subnational, local 

level estimates of victimization. The 

goal of this test is to generate a survey 

that could parallel National Crime 

Victimization Survey (NCVS) and 

Uniform Crime Report (UCR) estimates 

over time, rather than replicate either of 

them, and could be used to assess 

whether local initiatives are correlated 

with changes in crime rates. A 

secondary goal is to assess change over 

time, as the Field Test will be 

administered over two years, with a 

cross-sectional address-based sample 

survey in 2015 and a second addressbased sample survey 2016. The rationale 

for collecting data in two years is that 

we are able to assess the ability of the 

instruments to detect change over time. 

An additional feature of the surveys 

being tested is the inclusion of a set of 

questions on perceptions of 

neighborhood safety, fear of crime, and 

police effectiveness, which would allow 

the survey to be used to assess changes 

in these perceptions as well. This 

information is not currently available 

from the NCVS. 

(5) An estimate of the total number of 

respondents and the amount of time 

estimated for an average respondent to 

respond: Over the two year period 

approximately 200,400 households are 

expected to complete the survey. The 

sample is divided into two groups by 

instrument version: ASC1 person-level 

survey and ASC2 incident-level survey. 

Over the two waves, for both versions, 

approximately 25% of households 

interviewed in year 1 will be reinterviewed in year 2. 

• The first group of 100,200 

households will receive the ASC1, a 

person-level survey to measure 

prevalence or the number of adult 

household members victimized by one 

or more types of violent crime and the 

number of households victimized by 

types of property crime. The expected 

burden placed on these respondents is 

12 minutes per respondent for a total of 

20,040 burden hours for both years. 

• The second group of 100,200 

households will receive the ASC2, an 

incident-level survey to measure the 

number of victimization incidents 

experienced by all adult household 

members. The expected burden placed 

on these respondents is 12.5 minutes for 

a total of 17,535 burden hours. 

(6) An estimate of the total public 

burden (in hours) associated with the 

collection: The total respondent burden 

is approximately 37,575 hours. 

If additional information is required 

contact: Jerri Murray, Department 

Clearance Officer, United States 

Department of Justice, Justice 

Management Division, Policy and 

Planning Staff, Two Constitution 

Square, 145 N Street NE., 3E.405B, 

Washington, DC 20530. 

Dated: December 8, 2014. 

Jerri Murray, 

Department Clearance Officer for PRA, U.S. 

Department of Justice. 

[FR Doc. 2014–29066 Filed 12–10–14; 8:45 am] 

BILLING CODE 4410–18–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Manufacturer of Controlled 

Substances Registration: Johnson 

Matthey Pharmaceutical Materials, Inc. 

AGENCY: Drug Enforcement 

Administration, Department of Justice. 

ACTION: Notice of registration. 

SUMMARY: Johnson Matthey 

Pharmaceutical Materials, Inc. applied 

to be registered as a manufacturer of 

certain basic classes of controlled 

substances. The DEA grants Johnson 

Matthey Pharmaceutical Materials, Inc. 

registration as a manufacturer of the 

controlled substances. 

SUPPLEMENTARY INFORMATION: By notice 

dated January 15, 2014, and published 

in the Federal Register on February 4, 

2014, 79 FR 6633, Johnson Matthey 

Pharmaceutical Materials, Inc., 

Pharmaceutical Service, 25 Patton Road, 

Devens, Massachusetts 01434, applied 

to be registered as a manufacturer of 

certain basic classes of controlled 

substances. No comments or objections 

were submitted to this notice. 

The Drug Enforcement 

Administration (DEA) has considered 

the factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Johnson Matthey Pharmaceutical 

Materials, Inc. to manufacture the basic 

classes of controlled substances is 

consistent with the public interest and 

with United States obligations under 

international treaties, conventions, or 

protocols in effect on May 1, 1971. The 

DEA investigated the company’s 

maintenance of effective controls 

against diversion by inspecting and 

testing the company’s physical security 

systems, verifying the company’s 

compliance with state and local laws, 

and reviewing the company’s 

background and history. 

Therefore, pursuant to 21 U.S.C. 

823(a), and in accordance with 21 CFR 

1301.33, the above-named company is 

granted registration as a bulk 

manufacturer of the basic classes of 

controlled substances: 

Controlled substance Schedule 

Amphetamine (1100) .................... II 

Methylphenidate (1724) ................ II 

Nabilone (7379) ............................ II 

Hydrocodone (9193) ..................... II 

Alfentanil (9737) ........................... II 

Remifentanil (9739) ...................... II 

Sufentanil (9740) .......................... II 

The company plans to utilize this 

facility to manufacture small quantities 

mstockstill on DSK4VPTVN1PROD with NOTICES

Federal Register / Vol. 79, No. 238 / Thursday, December 11, 2014 / Notices 73629 

of the listed controlled substances in 

bulk and to conduct analytical testing in 

support of the company’s primary 

manufacturing facility in West Deptford, 

New Jersey. The controlled substances 

manufactured in bulk at this facility will 

be distributed to the company’s 

customers. 

Dated: November 25, 2014. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator. 

[FR Doc. 2014–29117 Filed 12–10–14; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Manufacturer of Controlled 

Substances Registration: Sigma 

Aldrich Research Biochemicals, Inc. 

AGENCY: Drug Enforcement 

Administration, Department of Justice. 

ACTION: Notice of registration. 

SUMMARY: Sigma Aldrich Research 

Biochemicals, Inc., applied to be 

registered as a manufacturer of certain 

basic classes of controlled substances. 

The DEA grants Sigma Aldrich Research 

Biochemicals, Inc. registration as a 

manufacturer of those controlled 

substances. 

SUPPLEMENTARY INFORMATION: By notice 

dated January 15, 2014, and published 

in the Federal Register on February 4, 

2014, 79 FR 6633, Sigma Aldrich 

Research Biochemicals, Inc. 1–3 

Strathmore Road, Natick, Massachusetts 

01760–2447, applied to be registered as 

a manufacturer of certain basic classes 

of controlled substances. No comments 

or objections were submitted to this 

notice. 

The Drug Enforcement 

Administration (DEA) has considered 

the factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Sigma Aldrich Research Biochemicals, 

Inc. to manufacture the basic classes of 

controlled substances is consistent with 

the public interest and with United 

States obligations under international 

treaties, conventions, or protocols in 

effect on May 1, 1971. The DEA 

investigated the company’s maintenance 

of effective controls against diversion by 

inspecting and testing the company’s 

physical security systems, verifying the 

company’s compliance with state and 

local laws, and reviewing the company’s 

background and history. 

Therefore, pursuant to 21 U.S.C. 

823(a), and in accordance with 21 CFR 

1301.33, the above named company is 

granted registration as a bulk 

manufacturer of the basic classes of 

controlled substances listed: 

Controlled substance Schedule 

Cathinone (1235) .......................... I 

Methcathinone (1237) .................. I 

Mephedrone (4-Methyl-Nmethylcathinone) (1248).I 

Aminorex (1585) ........................... I 

Alpha-ethyltryptamine (7249) ....... I 

Lysergic acid diethylamide (7315) I 

Tetrahydrocannabinols (7370) ..... I 

4-Bromo-2,5- 

dimethoxyamphetamine (7391).

I 

4-Bromo-2,5- 

dimethoxyphenethylamine 

(7392).

I 

4-Methyl-2,5- 

dimethoxyamphetamine (7395).

I 

2,5-Dimethoxyamphetamine 

(7396).

I 

3,4-Methylenedioxyamphetamine 

(7400).

I 

N-Hydroxy-3,4- 

methylenedioxyamphetamine 

(7402).

I 

3,4-Methylenedioxy-Nethylamphetamine (7404).I 

3,4- 

Methylenedioxymethamphetamine (MDMA) (7405).

I 

Dimethyltryptamine (7435) ........... I 

Psilocybin (7437) .......................... I 

5-Methoxy-N, Ndiisopropyltryptamine (7439).I 

1-[1-(2- 

Thienyl)cyclohexyl]piperidine 

(TCP) (7470).

I 

N-Benzylpiperazine (BZP) (7493) I 

MDPV (3,4- 

Methylenedioxypyrovalerone) 

(7535).

I 

Methylone (3,4-Methylenedioxy-Nmethylcathinone) (7540).I 

Heroin (9200) ............................... I 

Normorphine (9313) ..................... I 

Amphetamine (1100) .................... II 

Methamphetamine (1105) ............ II 

Nabilone (7379) ............................ II 

1-Phenylcyclohexylamine (7460) II 

Phencyclidine (7471) .................... II 

Cocaine (9041) ............................. II 

Codeine (9050) ............................. II 

Ecgonine (9180) ........................... II 

Levomethorphan (9210) ............... II 

Levorphanol (9220) ...................... II 

Meperidine (9230) ........................ II 

Metazocine (9240) ........................ II 

Methadone (9250) ........................ II 

Morphine (9300) ........................... II 

Thebaine (9333) ........................... II 

Levo-alphacetylmethadol (9648) .. II 

Remifentanil (9739) ...................... II 

Sufentanil (9740) .......................... II 

Carfentanil (9743) ......................... II 

Fentanyl (9801) ............................ II 

The company plans to manufacture 

reference standards. 

Dated: November 25, 2014. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator. 

[FR Doc. 2014–29119 Filed 12–10–14; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF LABOR 

Employee Benefits Security 

Administration 

Proposed Extension of Information 

Collection Request Submitted for 

Public Comment; Revisions to 

Coverage of Certain Preventive 

Services Under the Affordable Care 

Act 

AGENCY: Employee Benefits Security 

Administration, Department of Labor. 

ACTION: Notice. 

SUMMARY: The Department of Labor (the 

Department), in accordance with the 

Paperwork Reduction Act of 1995 (PRA 

95) (44 U.S.C. 3506(c)(2)(A)), provides 

the general public and Federal agencies 

with an opportunity to comment on 

proposed and continuing collections of 

information. This helps the Department 

assess the impact of its information 

collection requirements and minimize 

the reporting burden on the public and 

helps the public understand the 

Department’s information collection 

requirements and provide the requested 

data in the desired format. Currently, 

the Employee Benefits Security 

Administration is soliciting comments 

on the revision of the Coverage of 

Certain Preventive Services Under the 

Affordable Care Act information 

collection to reflect the new option of 

notifying the Department of Health and 

Human Services of the respondents’ 

objections to providing coverage in 

response to the Supreme Court of the 

United States’ interim order in 

connection with an application for an 

injunction in the pending case of 

Wheaton College v. Burwell. A copy of 

the information collection request (ICR) 

may be obtained by contacting the office 

listed in the ADDRESSES section of this 

notice. 

DATES: Written comments must be 

submitted to the office shown in the 

Addresses section on or before February 

9, 2015. 

ADDRESSES: Direct all written comments 

regarding the information collection 

request and burden estimates to G. 

Christopher Cosby, Office of Policy and 

Research, Employee Benefits Security 

Administration, U.S. Department of 

Labor, 200 Constitution Avenue NW., 

Room N–5718, Washington, DC 20210. 

Telephone: (202) 693–8410; Fax: (202) 

mstockstill on DSK4VPTVN1PROD with NOTICES